Location History:
- Lausanne, CH (2018)
- Epalinges, CH (2020)
Company Filing History:
2 out of 541 
1 out of 1 
1 out of 21 Years Active: 2018-2020
Title: Patricius Henrikus Cornelis Van Berkel: Innovator in Antibody-Drug Conjugates
Introduction
Patricius Henrikus Cornelis Van Berkel is a notable inventor based in Epalinges, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 2 patents, his work has the potential to impact the treatment of various disorders.
Latest Patents
Van Berkel's latest patents include innovative approaches to antibody-drug conjugates. One of his patents focuses on pyrrolobenzodiazepine-antibody conjugates, which are designed for treating disorders characterized by the presence of CD25+ve cells. Another patent involves humanized anti-Tn-MUC1 antibodies and their conjugates, which include conjugates comprising pyrrolobenzodiazepines (PBDs) with a labile protecting group linked to the antibody.
Career Highlights
Throughout his career, Van Berkel has worked with prominent companies in the biotechnology sector. He has been associated with Medimmune Limited and ADC Therapeutics S.A., where he has contributed to groundbreaking research and development in the field.
Collaborations
Van Berkel has collaborated with esteemed colleagues, including Philip Wilson Howard and David Gareth Williams. These partnerships have further enhanced his research and innovation in antibody-drug conjugates.
Conclusion
Patricius Henrikus Cornelis Van Berkel is a distinguished inventor whose work in antibody-drug conjugates is paving the way for new therapeutic options. His contributions to the field are invaluable and continue to inspire advancements in biotechnology.